FILGRASTIM
Shwachman-Diamond Syndrome
Roswell Park Cancer Instituteprotein_peptidePhase 2/3Dormant
BB
70/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 57/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the Shwachman-Diamond Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Fred Hutchinson Cancer Center | Phase 2/3 | BB |
Cyclophosphamide Roswell Park Cancer Institute | Phase 2/3 | BB |
Busulphan Masonic Cancer Center, University of Minnesota | Phase 2/3 | BB |
METHOTREXATE Fred Hutchinson Cancer Center | Phase 2 | B |
Equine Atg Masonic Cancer Center, University of Minnesota | Phase 2/3 | B |
View all 16 →
Same molecule, other indications
FILGRASTIM is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →